Albert Lands $55 Million Series B Led By TCV for Chemistry-Native AI

Albert has raised $55 million in a Series B round led by TCV, according to an announcement reported by Pulse 2.0. The money funds the company's push to scale what it calls chemistry-native AI for research and development.

That figure is the headline. But the more telling detail sits in the phrasing: chemistry-native. Albert isn't layering a general-purpose language model on top of lab workflows. It builds AI around chemistry itself — the discipline shapes the architecture, not the other way round.

What does the $55 million buy?

Series B capital at this size typically goes to three things: headcount, compute and commercial expansion. Albert's stated target, per the Pulse 2.0 report, is scale — taking its chemistry-native AI from a promising R&D tool to something labs and enterprises run daily.

TCV leading the round matters here. The firm backs growth-stage technology companies, and its involvement signals investors now see scientific AI as a category with durable demand rather than a research curiosity. A $55 million check is a bet that chemistry-specific AI can carry enterprise contracts, not just pilot programs.

Why does 'chemistry-native' matter?

Most AI tools in industrial R&D today are adapted from generic models — trained broadly, then pointed at chemistry problems. That approach produces impressive demos and uneven lab results, because chemistry's constraints are unforgiving: a wrong molecule is a failed experiment, not a paraphrase.

Albert's positioning, as captured in its announcement, inverts that. The AI is designed with chemistry at its foundation, which the company argues makes it more reliable for actual research and development work — the slow, expensive part of bringing products to market.

Takeaway: the differentiation isn't the model size. It's where chemistry sits in the stack.

Who is backing it?

TCV led the Series B. The round size — $55 million — places Albert among the better-funded players in scientific AI at its stage, and gives it runway to compete for R&D customers against both startups and the large-model platforms moving into science tooling.

No valuation was disclosed in the announcement as reported by Pulse 2.0.

What comes next?

The company says the capital scales its chemistry-native AI for R&D. Watch two things: whether Albert converts that funding into named enterprise deployments, and whether chemistry-native architecture measurably outperforms adapted general models in published results. The $55 million buys time to prove both.